Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AK1910 in Healthy Subjects and Patients With Systemic Lupus Erythematosus
jRCT2071230085Phase 1Active, not recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of SBI-3150 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Plasma concentration of compound(s) and Number of participants with adverse events. Started Nov 2023; status: active, not recruiting.
02
Drugs
SBI-3150
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071230085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230085.